N/A N=183 Management of Myelomeningocele Study (MOMS)
Meningomyelocele · Spinal Dysraphism
Primary: Infant Death or Need for Ventricular Shunt by 1 Year of Life — 66; 90 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=55 MiDAS II (Mild® Decompression Alternative to Open Surgery): Vertos Mild Patient Evaluation Study
Lumbar Spinal Stenosis
Primary: Changes in Back Pain as Measured by a 10-point Visual Analog Scale (VAS). — 3.59 units on a scale — p=<0.0001
N/A N=16 Functional Change With MMS
Muscle Weakness
Primary: Change in Body Satisfaction Questionnaire From Baseline to 1-month Post-Treatment Follow-up Visit — 8.6 units on a scale
N/A N=89 (MIST1)-Part 1: Assessment & Feasibility of Post-Symptoms Evaluation
Patient Safety · Manipulation, Spinal
Primary: Number of Patient Encounters That Report a New or Worsening Symptom — 8 Participants
N/A N=138 MiDAS III (Mild® Decompression Alternative to Open Surgery): Vertos Mild Patient Evaluation Study
Lumbar Spinal Stenosis
Primary: Percentage of Participants With a 2-point Improvement in Visual Analogue Scale — 65.71; 46.15 percentage of responders
N/A N=250 Minimally Invasive Surgery (MIS) Database for the Purpose of Research
Morbid Obesity · Hernia · Colorectal Cancer
Primary: Post Operative Outcomes — 27; 0; 6; 4 participants
Phase 4 N=78 MiDAS I (Mild® Decompression Alternative to Open Surgery): Vertos Mild Patient Evaluation Study
Lumbar Spinal Stenosis
Primary: Mean Change in Back Pain as Measured by a 10-point Visual Analog Scale (VAS). — 3.21 units on a scale — p=<0.0001
N/A N=47 Evaluation of the Performance of the Motus Cleansing System (MCS)
CRC
Primary: Performance of MCS in Cleansing a Poorly Prepared Colon. — 46; 9 Participants — p=<0.01
N/A N=265 Michigan Stroke Transitions Trial
Acute Stroke
Primary: Change From Baseline (7-days Post Discharge) to 90-days in the PROMIS-10 Global Quality of Life, Physical Health T-scores (Patient) — 0.293; 1.263; 3.663 change in…
Phase 2 N=7 HFS (High-Fiber Supplement) in MS (Multiple Sclerosis)
Multiple Sclerosis
Primary: Assess the Effect of NBT-NM108 on Serum TNF-alpha Levels in MS Patients — 25.62; 22.58; 20.73 pg/ml
Phase 2 N=58 AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients
Multiple System Atrophy, MSA
Primary: Striatum Brain Region: Change From Baseline in Microglia Activation Via Positron Emission Tomography(PET) — -0.23; 0.12; -0.35 ml/cc — p=0.13
N/A N=30,209 Methicillin-resistant Staphylococcus Aureus (MRSA) Skin and Soft Tissue Infection (SSTI) Prevention in Military Trainees
Staphylococcus Aureus · MRSA Skin Infections · Staphylococcal Skin Infections
Primary: Incidence of Skin and Soft Tissue Infection (SSTI) — 303; 439; 461 participants
N/A N=10 Mobile After-Care Intervention to Support Post-Hospital Transition (MACS)
Psychotic Disorders
Primary: Client Satisfaction Questionnaire (CSQ) — 19.2 units on a scale
N/A N=183 Computer Assisted Cognitive Rehabilitation for Persons With Multiple Sclerosis
Multiple Sclerosis
Primary: Neuro-cognitive Competence in Daily Living - California Verbal Learning Test-II — 56.1; 53.6 units on a scale — p=0.926
N/A N=80 The Second-Generation MCCG for Upper Gastrointestinal Tract.
Capsule Endoscopy
Primary: Circumferential Visualization of the Z-line — 0; 5; 5; 7 Participants
N/A N=43 Micra Accelerometer Sensor Study 2
Bradyarrhythmia
Primary: Waveform and Components of Accelerometer Signal — 0.15601; 0.19222; 0.14398 g (unit (g) represent acceleration)
N/A N=20 MS Spinal Mobilisation Study
Multiple Sclerosis
Primary: Participant Muscle Stiffness Measure — 350.83; 240.07 Newton-metres
Phase 2 N=37 ATX-MS-1467 in Multiple Sclerosis
Multiple Sclerosis
Primary: Change From Baseline in the Average Number of Time Constant 1 (T1) Contrast-enhanced Lesions (CELs) Over On-treatment Scans — 7.4; -2.4 lesions
Phase 2 N=73 POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler
Relapsing-remitting Multiple Sclerosis · RRMS
Primary: Summary of Raw Number of Cumulative Combined Unique Active Lesions in Patients With Relapsing Remitting Multiple Sclerosis by Visit and Treatment — 2.4; 3.2; 3.9; 5.4…
Phase 2 N=21 Stem Cells in Rapidly Evolving Active Multiple Sclerosis
Multiple Sclerosis
Primary: Number of Adverse Events Assessed by CTCAE v4.0 — 5; 0 total events
Phase 3 N=100 The Use of Methylsulfonylmethane (MSM) in the Treatment of Low Back Pain
Low Back Pain
Primary: Pain Level — 3.4; 3.7; 2.8; 2.9 score on a scale
N/A N=427 PiPT in ADSM With MSD
Chronic Pain · Musculoskeletal Diseases or Conditions
Primary: Change in Pain Disability Index (PDI) Score — 0; 33 Change in PDI score
Phase 2 N=32 Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis
Multiple Sclerosis
Primary: Percentages of Patients With Treatment-emergent Adverse Events (TEAEs) or Treatment-emergent Serious Adverse Events (TESAEs) — 100; 100; 88.9; 100 percentage of…
Phase 4 N=219 Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)
Multiple Sclerosis
Primary: Percentage of Participants With No Evidence of Disease Activity (Three Parameter [NEDA-3]) During Year 3 to 4 — 54.23 percentage of participants
Phase 2 N=24 Treatment of Degenerative Disc Disease With Allogenic Mesenchymal Stem Cells (MSV)
Degenerative Disc Disease · Intervertebral Disc Disease · Low Back Pain
Primary: Pain and Disability Evaluation — 0.28; 0.15 scores from 0 to 1
Phase 4 N=120 Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns
Multiple Sclerosis · Urinary Bladder Diseases
Primary: Change From Baseline in the King's Health Questionnaire (KHQ) Domain Scores — 39.7; 2.5; 60.7; 1.2 Scores on a Scale
Phase 4 N=138 Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC)
Ulcerative Colitis
Primary: Clinical Recurrence of Ulcerative Colitis (UC) During the Maintenance Phase at 6 Months — 46; 150; 11 participants
Phase 2 N=24 Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis
Multiple Sclerosis
Primary: Change From Baseline in Physical Health Composite Score - Multiple Sclerosis Quality of Life (MSQOL) 54 Instrument — 53.85; 44.07; 8.21; 7.03 score on a scale (100…
Phase 4 N=89 Multicenter, Randomized, Open-label Study to Assess Whether Treatment With Mycophenolate Sodium (MPS) Allows Higher Dose Optimization Versus Mycophenolate Mofetil (MMF) Leading to a Dose Reduction of Tacrolimus. Maximiza Study.
Prophilaxis of Acute Rejection in Patients Receiving a Renal Allograft
Primary: Number of Participants Achieving at Least Two Mycophenolic Acid (MPA) Dose Steps Higher and Reducing Tacrolimus Dose at the End of the Study — 0; 0; 43; 38 number of…
Phase 4 N=38 Study of Epidural Steroid Injection (ESI) Versus Minimally Invasive Lumbar Decompression (Mild®) in Patients With Symptomatic Lumbar Central Canal Stenosis
Lumbar Spinal Stenosis
Primary: Mean Change in VAS — 2.52; 0.06 units on a scale — p=<0.05